Resveratrol suppresses interleukin‐6 expression through activation of sirtuin 1 in hypertrophied H9c2 cardiomyoblasts

• Published in: Journal of cellular physiology Vol. 235; no. 10; pp. 6969 - 6977
• Main Authors: Akhondzadeh, Fariba, Astani, Akram, Najjari, Razieh, Samadi, Morteza, Rezvani, Mohammad Ebrahim, Zare, Fatemeh, Ranjbar, Ali Mohammad, Safari, Fatemeh
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2020
• Subjects: Activation; Angiotensin; Angiotensin II; Angiotensin II - pharmacology; Animals; cardiac hypertrophy; Cardiomegaly - drug therapy; Cardiomegaly - metabolism; Cell size; Cell Survival - drug effects; Cell viability; Cells, Cultured; Cytokines; Gene expression; Gene Expression - drug effects; Glycoprotein gp130; H9c2, Resveratrol; Histone deacetylase; Hypertrophy; IL‐6; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Interleukin-6 - metabolism; Interleukins; Myocytes, Cardiac; Pathogenesis; Polymerase chain reaction; Proteins; Rats; Resveratrol; Resveratrol - pharmacology; RNA, Messenger - metabolism; SIRT1 protein; Sirtuin 1 - metabolism; Transcription; Transcription, Genetic - drug effects; H9c2, Resveratrol; cardiac hypertrophy; angiotensin II; IL-6

Inflammatory cytokine, interleukin‐6 (IL‐6), plays an important role in the pathogenesis of cardiac hypertrophy. Recent studies have documented that resveratrol exhibits cardioprotective effects. The present study attempts to explore whether resveratrol suppreses IL‐6 in hypertrophied H9c2 cardiomyo...